Drug intelligence / Profile preview

isaridin e

Development stage
Unknown
Lead developer
Sun Yat-sen University
Modality
Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
Administration
Unknown
01

Overview

Isaridin E is a **marine-derived cyclohexadepsipeptide** isolated from Beauveria felina, a fungal source[2][6]. It is a **small molecule** with potent **antiplatelet**, **antithrombotic**, and **anti-inflammatory** properties[1][2][3][4]. Pharmacologically, isaridin E inhibits ADP-induced platelet activation by selectively interfering with platelet secretion and aggregation, which are central to arterial thrombosis in cardiovascular disease. It **concentration-dependently reduces ADP-induced platelet activation** without affecting collagen- or thrombin-induced aggregation[1]. Isaridin E further reduces von Willebrand factor (vWF) secretion and blocks vWF binding to integrin αvβ3, thereby alleviating endothelial hyperpermeability and inflammation, especially relevant in sepsis models[2][5]. Its anti-inflammatory action is also mediated via suppression of the TLR4/NF-κB signaling pathway[3]. Isaridin E demonstrates a low bleeding risk compared to established agents like clopidogrel[1][4].

Other names
isaridin e
02

Targets

P2Y (P2Y receptors)von Willebrand factor–integrin alpha-V beta-3–focal adhesion kinase/Src signaling axis (vWF–αvβ3–FAK/Src axis)P2Y12 (Purinergic P2Y12 receptor)αVβ3 (Integrin αVβ3)NF-κBTLR4 (Toll-like receptor 4)BB-031 (Von Willebrand factor)

Beyond the preview

Go deeper on isaridin e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on isaridin e.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call